Orally Delivered Nanotherapeutics with miRNA-497 Supplying for Inflammatory Bowel Disease
ACS Applied Materials & Interfaces · 05.08.2026 · 18 (30) · 40566-40575
DOI: 10.1021/acsami.6c11703 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, online erschienen am 20.07.2026. Verfasst von Hanlin Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang550004, China. Hauptthemen laut MEDLINE: MicroRNAs, Inflammatory Bowel Diseases, Nanoparticles, Metal-Organic Frameworks. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Health Commission of Guizhou Province, Affiliated Hospital of Guizhou Medical University, Department of Education of Guizhou Province.
Abstract (Originalsprache)
The excessive generation of reactive oxygen species (ROS) contributes to the inflammatory process in inflammatory bowel disease (IBD), and ROS-scavenging therapy, which can promote tissue repair, has emerged as a promising therapeutic strategy for managing IBD and other inflammatory diseases. Although ROS-scavenging therapy holds significant therapeutic potential for the management of IBD, systemic off-target effects remain a major limitation. Recent studies have identified microRNA-497 (miR-497) as a promising therapeutic target for IBD as it can polarize proinflammatory M1 macrophages to a tissue-repair phenotype, promoting the clearance of ROS and potentially alleviating the symptoms of IBD. Despite its therapeutic potential, the poor stability and limited cellular uptake of miR-497 pose significant barriers to its clinical use. To address these limitations, a delivery strategy based on manganese-doped metal−organic framework (Mn-MOF) nanoparticles labeled with miR-497 (Mn-MOF@miR-497) was developed to effectively inhibit the production of proinflammatory cytokines and restore immunological tolerance in enterocytes disrupted by proinflammatory stimuli. The topical administration of Mn-MOF@miR-497 exhibited significant therapeutic efficacy in a murine model of IBD induced by dextran sulfate sodium (DSS) without any observable toxicity. This innovative nanotherapeutic strategy demonstrates remarkable potential as a targeted treatment approach for IBD, holding promise for exploring innovative therapeutic regimens for IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Affiliated Hospital of Guizhou Medical University, Guiyang550004, China.
- Department of Gastroenterology, Affiliated Hospital of Guizhou Medical University, Guiyang550004, China.
- Department of Gastroenterology, Xingyi People's Hospital, Xingyi562400, China.
- Guizhou Provincial Key Laboratory for Digestive System Diseases, Affiliated Hospital of Guizhou Medical University, Guiyang550004, China.
ORCID-Profile: Hanlin Liu, Qi Liu
Förderung
- Health Commission of Guizhou Province
- Affiliated Hospital of Guizhou Medical University
- Department of Education of Guizhou Province
- Science and Technology Program of Guizhou Province
Zitieren
APA
Liu, H., Mu, Q., Shi, Q., Ran, S., Yang, H., Yao, Y., Wang, W., & Liu, Q. (2026). Orally Delivered Nanotherapeutics with miRNA-497 Supplying for Inflammatory Bowel Disease. ACS Applied Materials & Interfaces, 18(30), 40566-40575. https://doi.org/10.1021/acsami.6c11703
Vancouver
Liu H, Mu Q, Shi Q, Ran S, Yang H, Yao Y, et al. Orally Delivered Nanotherapeutics with miRNA-497 Supplying for Inflammatory Bowel Disease. ACS Applied Materials & Interfaces. 2026;18(30):40566-40575. doi:10.1021/acsami.6c11703
BibTeX
@article{Liu2026,
author = {Liu, Hanlin and Mu, Qiong and Shi, Qing and Ran, Suye and Yang, Hong and Yao, Yiran and Wang, Wenjuan and Liu, Qi},
title = {Orally Delivered Nanotherapeutics with miRNA-497 Supplying for Inflammatory Bowel Disease},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
volume = {18},
number = {30},
pages = {40566--40575},
doi = {10.1021/acsami.6c11703}
}
EUVIMED